- Home
- IONS
as 01-17-2025 4:00pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 6.0B | IPO Year: | 1991 |
| Target Price: | $62.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $31.41 - $52.49 | Next Earning Date: | 02-19-2025 |
| Revenue: | $803,067,000 | Revenue Growth: | 30.57% |
| Revenue Growth (this year): | -19.89% | Revenue Growth (next year): | 10.85% |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hayden Michael R | IONS | Director | Dec 23 '24 | Buy | $36.22 | 5,000 | $181,078.75 | 32,719 | |
| LOSCALZO JOSEPH | IONS | Director | Nov 12 '24 | Sell | $37.86 | 13,508 | $511,426.39 | 32,251 | |
| Swayze Eric | IONS | EVP Research | Nov 12 '24 | Sell | $37.92 | 1,194 | $45,277.67 | 33,713 | |
| Monia Brett P | IONS | Chief Executive Officer | Nov 12 '24 | Sell | $38.05 | 6,630 | $252,294.04 | 167,393 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
Zacks
9 days ago
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
PR Newswire
10 days ago
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
Simply Wall St.
a month ago
Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%?
Morningstar Research
a month ago
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
Morningstar Research
a month ago
Analyst Report: Ionis Pharmaceuticals, Inc.
Pharmaceutical Technology
a month ago
FDA approves Ionis’ TRYNGOLZA for FCS treatment
Zacks
a month ago
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
Compare IONS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.